Drugs / cenersen
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00967512 | Jan 2012 | acute myeloid leukemia | Eleos, Inc. | Withdrawn | No outcome recorded |
| Phase 2 | NCT00636155 | Feb 2008 → Aug 2011 | chronic lymphocytic leukemia/small lymphocytic lymphoma | David Rizzieri | Terminated | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02243124 Comparator | Sep 2014 → Sep 2015 | myelodysplastic syndrome | Eleos, Inc. | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00074737 Comparator | Apr 2004 → May 2007 | acute myeloid leukemia | Eleos, Inc. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | cenersen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00636155 ↗ |
| Action | Inhibit | “Cenersen sodium is a drug that is designed to block the effects of a protein called p53.” NCT00074737 ↗ |
| Modality | Antisense oligonucleotide | “Cenersen sodium is one of a new class of drugs called antisense oligonucleotides (oligos).” NCT00074737 ↗ |
| Route | Intravenous | “cenersen IV infusion 0.3 mg/kg/day” NCT02243124 ↗ |
| Target | TP53 | “down-regulates the production of both wild-type and mutant p53” NCT02243124 ↗ |